Full Fasting for Health & Longevity - Quick Reference Sheet

Full Fasting for Health & Longevity

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

Complete withdrawal of food, water only, for days to a few weeks. In people with excess weight or raised blood pressure, supervised fasts of one to three weeks lower weight, waist size and blood pressure, often allowing blood-pressure drugs to be stopped. Much of the loss is water and lean tissue; gains fade within months unless the diet changes. (Full Review)

Protocol

Duration & Structure
4–21 days
7–14 days account for the majority of published clinical experience; 5 days is the shortest duration at which the systemic proteomic response is established
Method
Water-only or Buchinger
Water-only permits water alone; the Buchinger method provides roughly 75–250 kcal per day as vegetable broth, diluted juice and honey
Preparation & Refeeding
1–3 days in, one-third to one-half out
Preceded by 1–3 preparation days of reduced-calorie plant-based eating; the post-fast diet is part of the protocol, whole-plant-food or vegetarian
Time to effect
Weight & Blood Pressure
Substantial after week 1
Both fall from day 1 but only become substantial after the first week; benefits that outlast the fast require the post-fast dietary change and are assessed at six weeks and beyond
Deep Ketosis
Day 3–4
Ketones detectable in more than 95% of fasters by day 4; hunger typically disappears at about the same point
Subjective Complaints
Second week
Improvements in subjective complaints are usually reported in the second week; the systemic multi-organ response does not appear until after day 3

Benefits

Contraindications
  • Insulin and insulin secretagogues (glipizide, glyburide, glimepiride, repaglinide) without prescriber-directed dose adjustment
  • SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)
  • Lithium without close monitoring
  • Blood donation and elective surgery during the fast
  • Body mass index below 18.5 kg/m²
  • Pregnancy and lactation; children and adolescents
  • Type 1 diabetes and any history of ketoacidosis
  • Any current or historical eating disorder
  • Chronic kidney disease stage 4 or 5 (below 30 mL/min/1.73 m²); Child-Pugh Class B or C cirrhosis
  • Recent myocardial infarction (within 90 days); unstable angina; New York Heart Association Class III or IV heart failure
  • Congenital long QT syndrome or a history of ventricular arrhythmia; untreated hyperthyroidism
  • Porphyria; fatty acid oxidation disorders including MCAD deficiency
  • Active cancer with cachexia; dementia or any condition preventing reliable self-monitoring
  • Adults over 75 with established sarcopenia or frailty
Key Interactions
  • Metformin
  • Antihypertensives (lisinopril, losartan, amlodipine, metoprolol) and diuretics (hydrochlorothiazide, furosemide)
  • GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)
  • Warfarin and direct oral anticoagulants
  • Levothyroxine
  • QT-prolonging drugs (sotalol, amiodarone, citalopram, some antipsychotics, macrolide antibiotics)
  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin)
  • Acetaminophen (paracetamol)
  • Antacids, proton pump inhibitors and antihistamines
  • Supplements with additive blood-pressure-lowering effects (beetroot or dietary nitrate, garlic extract, hibiscus, magnesium, omega-3 fatty acids, potassium salts)
  • Supplements with additive glucose-lowering effects (berberine, cinnamon extract, chromium, alpha-lipoic acid, bitter melon, gymnema)
  • Caloric and protein-containing supplements (branched-chain amino acids, collagen, protein powders, medium-chain triglyceride oil, sweetened electrolyte drinks)
  • Herbal diuretics and stimulant laxatives (dandelion, uva ursi, senna, cascara)
  • Sauna, hot yoga and heat exposure; high-intensity or high-volume exercise; cold exposure

Risk & Side Effects

  • High: Loss of fat-free mass and total body water; transient symptom burden of fatigue, headache, dizziness, nausea and insomnia; rise in cholesterol during the fast; hyperuricemia and gout flare
  • Medium: Refeeding syndrome; regain of weight and complete loss of metabolic benefit; systemic inflammation and platelet activation; dilutional hyponatremia from water without sodium; gallstone formation; thiamine deficiency and Wernicke encephalopathy; hypoglycemia and ketoacidosis in people using glucose-lowering medication; cardiac arrhythmia from electrolyte depletion
  • Low: Reduced conversion of thyroid hormone; halitosis and oral changes; menstrual disruption and reproductive hormone suppression; precipitation or worsening of disordered eating
  • Speculative: Cumulative bone loss with repeated fasting cycles; net sarcopenia in older adults from repeated cycles

Monitoring

Marker Target Why
Seated and standing blood pressure <120/80 mmHg seated; <20 mmHg systolic drop on standing Primary efficacy marker and the main safety limit
Body weight Loss of 0.3–0.7 kg/day after day 3 Tracks fluid shift and energy deficit
Fat-free mass Loss limited to <5% of baseline The principal cost of the intervention
Serum potassium 4.0–4.5 mmol/L Prevents arrhythmia
Serum sodium 138–142 mmol/L Detects dilutional hyponatremia from water without sodium
Serum phosphate 1.0–1.4 mmol/L The defining marker of refeeding syndrome
Serum magnesium 0.85–1.0 mmol/L Supports potassium retention and cardiac stability
Uric acid <6.0 mg/dL (357 µmol/L) Predicts and tracks gout risk
Fasting glucose 70–90 mg/dL (3.9–5.0 mmol/L) Safety marker and efficacy marker
Glycated haemoglobin <5.4% Medium-term glycemic efficacy
Blood or urine ketones 2–5 mmol/L blood β-hydroxybutyrate Confirms the fast is metabolically real
Estimated glomerular filtration rate and creatinine >90 mL/min/1.73 m² Detects dehydration-related kidney injury
Lipid panel Low-density lipoprotein cholesterol <100 mg/dL Longer-term cardiometabolic efficacy
High-sensitivity C-reactive protein <1.0 mg/L Inflammatory response, which is disputed in this setting
Complete blood count Haemoglobin and platelets stable from baseline Detects haemoconcentration and platelet activation

Cadence: Baseline in the two weeks before the fast; daily during a supervised fast for weight, seated and standing blood pressure, heart rate, ketones and symptoms; laboratory electrolytes at baseline, at least twice weekly for fasts beyond 7 days, on the first and third days of refeeding and again at 4 weeks; follow-up laboratory work at 6 weeks and at 3–6 months

Qualitative Assessment

  • Hunger: typically disappears between days 2 and 4; hunger that persists or returns strongly after day 5 suggests the metabolic switch has not occurred or has been interrupted
  • Energy and mental clarity: usually deteriorates in days 1–3, then improves; a second deterioration after day 5 is a warning sign
  • Sleep quality: expected to worsen transiently; complete insomnia beyond a few nights warrants review
  • Dizziness on standing: expected and manageable; syncope, visual greying or falls are stopping criteria
  • Cold intolerance: expected, reflecting reduced thyroid conversion and energy expenditure
  • Mood: elevated mood is commonly reported after the first days; anxiety, irritability or low mood that deepens across the fast is a reason to stop
  • Halitosis and taste change: expected and cosmetic, confirming ketosis
  • Confusion, visual disturbance or unsteady gait: never normal; these are the presenting features of thiamine deficiency and require immediate medical attention